In pharmaceutical quality control, getting a result outside the approved specification is a serious matter. This type of result is commonly called OOS, which stands for Out of Specification.
An OOS result does not always mean that the product is defective. Sometimes the problem may arise in the laboratory, such as an incorrect dilution, a calculation error, an instrument issue, or a sample preparation mistake. In other cases, the result may be a true product or manufacturing failure.
This is why OOS investigation in the pharmaceutical industry is so important.
The purpose of an OOS investigation is not to make a failed result pass. The purpose is to find out what happened, why it happened, and whether the problem affected the product or the testing process.
The U.S. FDA defines OOS results as test results that fall outside approved specifications or acceptance criteria. This can include laboratory testing of raw materials, in-process materials, finished products, and other pharmaceutical materials.
In this article, we will discuss OOS in pharmaceutical QC, common causes, the OOS investigation procedure, retesting, resampling, root cause analysis, CAPA, and the difference between OOS and OOT.
What is OOS in the pharmaceutical industry?
OOS means Out of Specification.
A result is called OOS when it does not meet the approved specification or acceptance criteria for that particular test.
For example, suppose the approved assay specification for a tablet is
Assay: 95.0% to 105.0%
If the laboratory obtains an assay result of 93.5%, the result is outside the approved range.
Therefore, it is an OOS result.
Some common examples of OOS results in pharmaceutical QC include:
- Assay below or above specification
- Dissolution failure
- Related substances above the limit
- Content uniformity failure
- pH outside the specified range
- Water content failure
- Microbial limit failure
- Impurity failure
- Identification failure
- Weight variation failure
OOS results can occur during testing of raw materials, finished products, stability samples, and certain in-process materials.
Is an OOS Result Always a Product Failure?
No.
This is one of the most important things to understand about OOS investigation.
An OOS result tells us that the result is outside the specification. It does not automatically tell us why the result occurred.
There can be different causes.
For example, an assay result of 93.5% could happen because:
- The sample was diluted incorrectly.
- The standard was prepared incorrectly.
- The analyst made a calculation error.
- The instrument was not working properly.
- The sample was not representative.
- There was a manufacturing problem.
- The product actually has a low assay.
Therefore, the result needs to be investigated before a final conclusion is reached.
FDA guidance emphasizes that an OOS result should not be attributed solely to analytical error unless the investigation identifies a laboratory root cause.
Common Causes of OOS Results
There are many possible causes of an OOS result. They can generally be grouped into laboratory-related causes and manufacturing or process-related causes.
1. Analyst Error
An analyst may make a mistake while performing the test.
Some examples are
- Incorrect weighing
- Wrong dilution
- Incorrect pipetting
- Wrong sample quantity
- Incorrect calculation
- Using the wrong volumetric flask
- Using the wrong standard
- Not following the analytical method
- Incorrect preparation of reagents
- Incorrect instrument settings
For example, if the method requires 5 mL of sample but the analyst transfers 4 mL, the final concentration may differ from the expected concentration.
However, an analyst should not automatically be blamed whenever an OOS occurs. The investigation must be supported by evidence.
2. Instrument Problems
Analytical instruments can also cause unexpected results.
Common examples include:
- HPLC problems
- UV-Visible spectrophotometer problems
- Balance problems
- pH meter problems
- Incorrect calibration
- Detector problems
- Temperature problems
- Instrument maintenance issues
For an HPLC OOS investigation, the analyst may need to review the chromatogram, system suitability results, standard preparation, sample preparation, mobile phase preparation, calculations, and instrument performance.
3. Standard and Reagent Problems
Standards and reagents are important parts of pharmaceutical analysis.
Problems may occur because of:
- Expired reagent
- Incorrect reagent preparation
- Incorrect standard concentration
- Improper storage
- Contamination
- Incorrect potency correction
- Incorrect weighing
- Incorrect mobile phase preparation
For example, if a standard is prepared at the wrong concentration, the final assay result may be affected.
4. Sampling Error
Sometimes the problem is related to sampling.
Examples include:
- Incorrect sampling procedure
- Poor mixing
- Incorrect sampling location
- Contamination during sampling
- Insufficient sample quantity
- Improper sample storage
A laboratory can perform the test correctly but still obtain an unusual result if the sample does not properly represent the batch.
5. Manufacturing or Process Problems
An OOS result can also be a genuine manufacturing problem.
Possible causes include:
- Incorrect dispensing
- Poor mixing
- Incorrect mixing time
- Incorrect temperature
- Incorrect drying conditions
- Raw material variation
- Equipment malfunction
- Process parameter variation
- Granulation problems
- Compression problems
For example, poor mixing during tablet manufacturing could lead to an actual assay or content uniformity problem.
A full-scale investigation may therefore require review of manufacturing records, sampling procedures, equipment, raw materials, and previous batch history.
OOS Investigation Procedure
A proper OOS investigation procedure should be defined in the company's approved SOP.
The investigation should be timely, objective, well documented, and based on scientific evidence.
A simple way to understand the process is to divide it into two main stages:
Phase I: Initial Laboratory Investigation
Phase II: Full-Scale OOS Investigation
Phase I: Initial Laboratory Investigation
The first step is to determine whether there is an obvious laboratory-related cause.
The analyst and supervisor should review the test carefully.
The review may include:
- Original raw data
- Test method
- Calculations
- Sample preparation
- Standard preparation
- Reagent preparation
- Instrument status
- System suitability
- Chromatograms
- Weighing records
- Dilution details
- Laboratory equipment
- Previous relevant results
The analyst should also explain exactly how the test was performed.
For an HPLC assay OOS, for example, the investigation may check:
- Standard weight
- Standard potency
- Sample weight
- Dilution steps
- Volumetric flask used
- Pipette used
- Mobile phase preparation
- Chromatographic conditions
- System suitability
- Peak integration
- Calculations
If a clear laboratory error is identified and supported by evidence, the result can be evaluated in accordance with the company's approved procedure.
If no laboratory error is identified, the investigation should not simply stop.
Phase II: Full-Scale OOS Investigation
If the initial laboratory investigation does not identify a laboratory root cause, a broader investigation may be required.
This can involve:
- Quality Assurance
- Quality Control
- Production
- Engineering
- Maintenance
- Warehouse
- Process development
- Other relevant departments
The investigation may review:
- Batch manufacturing records
- Raw material history
- Manufacturing parameters
- Equipment records
- In-process results
- Previous batch results
- Deviations
- Change controls
- Stability data
- Complaints
- Previous OOS results
- Sampling procedures
FDA guidance describes this broader investigation as a full-scale OOS investigation when the initial laboratory assessment does not establish laboratory error.
The aim is to determine the root cause of the OOS result and assess its impact.
OOS Root Cause Analysis
Finding the root cause is one of the most important parts of an OOS investigation.
A weak investigation may simply state:
"Analyst error."
But this may not explain why the error happened.
A better investigation asks additional questions.
For example:
Why was the wrong pipette used?
Perhaps the pipettes looked similar.
Why did they look similar?
Maybe there was no clear identification system.
Why was there no identification system?
Perhaps the laboratory procedure did not clearly define identification requirements.
This approach can help identify the actual system-level cause.
Common tools used for root cause analysis include
- 5 Why analysis
- Fishbone diagram
- Failure Mode and Effects Analysis (FMEA)
- Process mapping
- Trend analysis
ICH Q9(R1) supports a science-based and risk-based approach to pharmaceutical quality risk management.
Retesting After an OOS Result
Retesting is another important part of OOS investigation.
One common mistake is to immediately repeat the test after obtaining an OOS result.
For example:
Initial result: 92.5%
Retest: 98.2%
It would be incorrect to simply ignore the original 92.5% result because the retest passed.
The reason for retesting must be scientifically justified and consistent with the approved procedure.
A company should never continue testing until it obtains a passing result.
The original result remains important information and should be properly documented.
FDA guidance specifically addresses the need for scientifically justified approaches to retesting and investigation rather than using repeated testing simply to obtain a passing result.
Resampling After OOS
Resampling is different from retesting.
Retesting generally involves testing the original sample or preparation again according to an approved and justified procedure.
Resampling means obtaining a new sample from the batch.
Resampling should not be used simply because the first sample failed.
There should be a documented scientific reason for taking another sample.
The sampling procedure, location, quantity, and reason for resampling should be clearly documented.
Appropriate procedures should govern any resampling or retesting following an OOS result.
OOS CAPA
After finding the root cause, appropriate CAPA may be required.
CAPA means:
Corrective Action and Preventive Action.
Corrective action deals with the current problem.
Preventive action aims to reduce the likelihood of the same problem recurring.
For example, suppose an investigation finds that an analyst repeatedly makes dilution mistakes because the analytical procedure is unclear.
Possible corrective actions could include:
- Review the affected analysis
- Correct the immediate problem
- Provide appropriate training
Preventive actions could include:
- Improve the SOP
- Add a clear dilution example
- Improve labeling
- Introduce an appropriate verification step
- Review similar analytical procedures
CAPA should be connected to the actual root cause.
Simply writing "analyst retraining completed" may not be enough if the real problem is a poorly designed procedure.
Recent FDA enforcement actions also show why companies need strong scientific justification for OOS root causes and effective CAPA.
OOS vs. OOT: What is the Difference?
OOS and OOT are related but different concepts.
OOS
OOS = Out of Specification
The result is outside the approved specification.
Example:
Specification: 95–105%
Result: 92%
This is OOS.
OOT
OOT = Out of Trend
The result may still be within specification but shows an unusual trend compared with previous results.
For example:
- 101.2%
- 100.8%
- 100.5%
- 100.2%
- 97.4%
The last result may still be within specification, but the downward trend warrants evaluation.
OOT monitoring can help identify possible problems before they become OOS.
Example of an OOS Investigation
Consider a tablet with an assay specification of
95.0%–105.0%
The analyst obtains:
93.8%
The result is OOS.
The analyst reports the result in accordance with the laboratory SOP.
The initial investigation checks:
- Sample weight
- Standard weight
- Standard potency
- Dilution
- Pipette
- Volumetric flask
- Instrument
- System suitability
- Chromatogram
- Calculations
During the investigation, the team discovered that the analyst used an incorrect dilution volume.
The error is supported by the original records and other evidence.
The investigation can then document the laboratory root cause in accordance with the applicable procedure.
However, if no laboratory error is found, the investigation should continue into the manufacturing and sampling areas.
This is why an OOS result should never be dismissed simply because a subsequent test is passing.
Common Mistakes in OOS Investigation
A few mistakes can weaken an OOS investigation.
1. Testing until the result passes
This is not a proper investigation approach.
2. Blaming the analyst without evidence
A conclusion should be supported by documented facts.
3. Ignoring the original result
The original OOS result is part of the investigation record.
4. Changing or deleting raw data
Original data must be properly maintained and traceable.
5. Performing unjustified retesting
Retesting should have a scientific and procedural basis.
6. Stopping the investigation too early
If no laboratory cause is found, the investigation may need to expand to include production, sampling, equipment, and other relevant areas.
7. Using the same generic CAPA every time
CAPA should address the actual root cause.
FDA inspection guidance highlights the importance of reviewing raw laboratory data and ensuring that OOS conclusions are supported by an appropriate investigation.
Important Points for QC Analysts
If you are working in pharmaceutical QC, remember these basic points:
- Report an OOS result according to your SOP.
- Do not hide or change the original result.
- Preserve the original data.
- Check calculations carefully.
- Review sample and standard preparation.
- Check instrument performance.
- Review system suitability.
- Investigate possible laboratory causes.
- Do not perform unjustified retesting.
- Do not resample without a documented reason.
- Look for the real root cause.
- Document every important step.
- Assess the potential impact on the batch.
- Implement appropriate CAPA when required.
Why OOS Investigation is Important in Pharmaceutical QC
Pharmaceutical products are used by patients, so product quality cannot be taken lightly.
A proper OOS investigation helps a company determine whether a problem is related to:
- Laboratory testing
- Sampling
- Raw materials
- Manufacturing
- Equipment
- Analytical methods
- Human factors
- The quality system
It also helps prevent similar problems in future batches.
Quality risk management should be based on scientific knowledge and ultimately support patient protection. ICH Q9(R1) also emphasizes that the level of effort and documentation should be appropriate to the level of risk.
Frequently Asked Questions About OOS
What is the full form of OOS in pharma?
OOS stands for Out of Specification.
What is an OOS investigation?
OOS investigation is a documented process used to determine why a pharmaceutical test result is outside its approved specification.
What are the common causes of OOS?
Common causes include analyst error, calculation error, instrument problems, standard or reagent problems, sampling issues, and genuine manufacturing or process problems.
Can an OOS result be retested?
Retesting may be performed when scientifically justified and permitted by the approved procedure. It should not be used simply to obtain a passing result.
What is OOS vs. OOT?
OOS means the result is outside the approved specification. OOT means a result may be within specification but shows an unusual trend compared with previous data.
What is CAPA in an OOS investigation?
CAPA means Corrective Action and Preventive Action. It is used to correct identified problems and reduce the chance of recurrence.
Conclusion
OOS investigation in the pharmaceutical industry is an important part of pharmaceutical quality control. An OOS result should never be treated as merely a failed test or as something that can be resolved by repeating the analysis.
The investigation should determine what happened and why.
The process normally begins with a laboratory investigation. If no clear laboratory cause is established, the investigation may need to expand to manufacturing, sampling, equipment, raw materials, and other relevant areas.
A good OOS investigation should be scientific, unbiased, well documented, and focused on the true root cause.
For QC analysts and QA professionals, understanding OOS investigations is also useful for pharmaceutical job interviews, as questions about OOS, retesting, resampling, root cause analysis, CAPA, and OOS vs OOT are common quality-related topics.
Most importantly, the goal of an OOS investigation is not to make the result pass. The goal is to understand the problem, protect product quality, and prevent it from happening again.
References
- U.S. FDA Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production.
- U.S. FDA, Pharmaceutical Quality Control Laboratories.
- ICH Q9(R1) Quality Risk Management.
